Vancouver, BC, December 6, 2019--Decipher Biosciences (formerly GenomeDx), a leader in the field of urologic cancer genomics, has announced a research collaboration with Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, to apply genomic tumor profiling using the Decipher® assay and GRID® software to identify prostate cancer patients on active surveillance who may benefit most from treatment with sipuleucel-T.